ArticleCureus2026
Myxofibrosarcomas Have Extremely Low Internal Echoes: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a rare case of myxofibrosarcoma characterized by extremely low internal echoes on ultrasonography, a feature that may serve as an important diagnostic clue. The patient was a 54-year-old woman with a medical history of treatment for primary breast cancer as well as axillary recurrence treatment. After a prolonged disease-free interval of 15 years, the patient detected an ipsilateral axillary mass and was referred to our hospital. Ultrasound revealed a well-circumscribed axillary mass, measuring 21 mm, with extremely low internal echoes. MRI of the axillary mass showed faintly high signals on fat-suppressed T1-weighted images, predominantly high signals on T2-weighted images, and persistent enhancement accompanied by small non-enhanced areas on dynamic studies. Positron emission tomography (PET) showed a maximal standardized uptake value (SUVmax) of 3.1. With a working diagnosis of either axillary re-recurrence or a form of axillary sarcoma, we successfully resected the axillary mass for both diagnostic confirmation and potential curative intent. Postoperative pathological evaluation demonstrated atypical stellate cells with abundant chromatin growing in sparse and focally dense patterns against a mucus-rich background. Immunostaining showed AE1/AE3 negativity and a Ki-67 labeling index of 40%, leading to a final diagnosis of myxofibrosarcoma. Given the patient's preferences and prior exposure to chemotherapy and radiotherapy for breast cancer, she did not receive any adjuvant therapy and has been followed without recurrence on an outpatient basis for 11 months. Diagnostic physicians should be aware that myxofibrosarcomas may exhibit extremely low internal echoes, weak high signals on fat-suppressed T1-weighted images, and low SUVmax values on PET, findings that are attributable to the mucus-rich background.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.